A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.

@article{Keiser2011AP1,
  title={A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.},
  author={Paul B. Keiser and Susan Biggs-Cicatelli and Elizabeth E. Moran and Deborah H Schmiel and Valerian B. Pinto and Roberta E. Burden and Lori B Miller and James E. Moon and Robert A. Bowden and James F. Cummings and Wendell D. Zollinger},
  journal={Vaccine},
  year={2011},
  volume={29 7},
  pages={1413-20}
}
This phase I clinical trial assessed the safety and immunogenicity of a native outer membrane vesicle (NOMV) vaccine prepared from an lpxL1(-) synX(-) mutant of strain 8570(B:4:P1.19,15:L8-5) of Neisseria meningitidis. Additional mutations enhance the expression of factor H binding protein variant 1 (fHbp v.1), stabilize expression of OpcA and introduce a second PorA (P1.22,14). Thirty-six volunteers were assigned to one of four dose groups (10, 25, 50 and 75 mcg, based on protein content) to… CONTINUE READING
53 Citations
31 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 53 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Characterization of an antibodydepletion assay for analysis of bactericidal antibody specificity

  • MoranEE ZollingerWD, DH Schmiel
  • Clin Vaccine Immunol
  • 2009

Similar Papers

Loading similar papers…